ABAX News Alert Abaxis Inc (ABAX) 58.48 12/25/2014 16:51:06

New Post Public Reply Private Reply Replies (0) Message Board

Dec 25, 2014 at 5:50 PM

Abaxis Inc (ABAX) 58.48 $ABAX

Neogen Q2 Earnings & Revenues Lag Estimates, Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 8:00AM CST
Since the earnings announcement, shares of Neogen Corp. (NEOG) rose about 1.2% to close at $48.28 in the last trading session.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), NEOG: 48.21 (-0.10), OSUR: 10.26 (+0.25)

Smith & Nephew Up on Post-Operative Wound Therapy Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:26PM CST
Smith & Nephew's (SNN) PICO Single Use NPWT is a revolutionary canister-free system that has been designed to promote optimal wound healing.
ICUI: 83.38 (+1.63), SNN: 38.18 (+0.14), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)

Uptrend Call Working As Abaxis Stock Rises 13.9% (ABAX)
Comtex SmarTrend(R) - Fri Dec 19, 10:04AM CST
SmarTrend identified an Uptrend for Abaxis (NASDAQ:ABAX) on October 31st, 2014 at $52.37. In approximately 2 months, Abaxis has returned 13.92% as of today's recent price of $59.66.
ABAX: 58.48 (+0.22)

Patterson Companies (PDCO) to Buy Holt Dental Supply - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 4:40PM CST
Distributor of dental, veterinary and rehabilitation supplies, Patterson Companies, Inc. (PDCO), recently announced an agreement to acquire Holt Dental Supply, Inc.
ABAX: 58.48 (+0.22), PDCO: 48.79 (-0.02), QSII: 15.73 (+0.23), XRAY: 53.76 (-0.24)

Is Boston Scientific (BSX) Worth Adding to Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:50PM CST
On Dec 16, 2014, Zacks Investment Research upgraded Boston Scientific Corporation (BSX) to a Zacks Rank #2 (Buy).
MGNX: 33.00 (+0.34), BSX: 13.13 (+0.07), ABAX: 58.48 (+0.22), HSP: 62.60 (-0.07)

PerkinElmer (PKI) Closes Acquisition of Perten Instruments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:00PM CST
The completion of the acquisition is not expected to have a material impact on PerkinElmer Inc.'s (PKI) results for the fourth quarter of 2014.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), PKI: 43.99 (-0.06), OSUR: 10.26 (+0.25)

Boston Scientific's Chronic Pain Cure Solution Tests Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 2:40PM CST
The study results are indicative of the fact that Boston Scientific's (BSX) next-generation Precision Spectra SCS System can offer sustainable respite for patients suffering from chronic low back pain.
BSX: 13.13 (+0.07), ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)

Medtronic (MDT) Launches 2 CRT Quadripolar Leads in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 1:20PM CST
Medtronic's (MDT) new leads can be implanted in patients with varying vessel sizes and curvatures, to facilitate better pumping efficiency of the heart in a wide range of heart failure patients.
ICUI: 83.38 (+1.63), MDT: 74.08 (+0.31), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)

Strong And Under The Radar: Abaxis (ABAX)
at The Street - Fri Dec 12, 2:10PM CST
Trade-Ideas LLC identified Abaxis (ABAX) as a strong and under the radar candidate
ABAX: 58.48 (+0.22)

Will Medtronic's Endurant AAA Stent Graft Last Long? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 1:40PM CST
Medtronic's (MDT) Endurant AAA stent graft system ??? a global leader in the coronary & structural heart device category ??? is compatible with a broad range of aortic anatomies.
ICUI: 83.38 (+1.63), MDT: 74.08 (+0.31), ABAX: 58.48 (+0.22), OSUR: 10.26 (+0.25)

St. Jude Medical's Quadra Allure Pacemaker Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 11:30AM CST
The Quadra Allure MP CRT-P expands St. Jude Medical Inc.'s (STJ) heart failure portfolio which includes the CardioMEMS HF Monitoring System, implantable cardioverter defibrillators, quadripolar and multi-point pacing systems.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), STJ: 66.67 (+0.67), OSUR: 10.26 (+0.25)

Agios Pharmaceuticals (AGIO) Looks Good: Stock Up 6.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:25AM CST
Agios Pharmaceuticals (AGIO) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), AGIO: 109.67 (+2.45), OSUR: 10.26 (+0.25)

TG Therapeutics, Inc. (TGTX) in Focus: Stock Soars 21.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:21AM CST
TG Therapeutics, Inc. (TGTX) was a big mover last session, as the company saw its shares rise by over 21% on the day.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), TGTX: 16.03 (+0.33), OSUR: 10.26 (+0.25)

Baxter Files Form 10 with SEC, Advances Baxalta Spin-off - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:40AM CST
In March this year, Baxter International Inc. (BAX) had announced its intention to separate its biopharmaceuticals and medical device segments into two independent companies - Baxter International Inc. and Baxalta Incorporated.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), BAX: 74.45 (-0.04), OSUR: 10.26 (+0.25)

Alere's HIV Combo Test Gets CLIA Waiver from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 11:20AM CST
Shares of Alere Inc. (ALR) rose 1.1% in the trading session after the news on Tuesday but pulled back to close the day lower at $37.86.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), ALR: 37.48 (+0.37), OSUR: 10.26 (+0.25)

Insider Trading Alert - COBZ, ABAX And EVTC Traded By Insiders
at The Street - Thu Dec 11, 10:15AM CST
Stocks with insider trader activity include COBZ, ABAX and EVTC
COBZ: 13.14 (+0.01), ABAX: 58.48 (+0.22), EVTC: 22.73 (+0.15)

Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit
PR Newswire - Fri Dec 05, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Craig Tockman, DVM, Vice President of Animal Health Sales and Marketing, will present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit on Thursday, December 11, 2014 at 3:35 p.m. ET. The conference will be held at the Bank of America Conference Center in Boston, MA.
ABAX: 58.48 (+0.22)

Strength Seen in Cardica (CRDC): Stock Moves 8.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:25AM CST
Cardica (CRDC) was a big mover last session, with shares rising nearly 9% on the day.
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), CRDC: 0.69 (unch), OSUR: 10.26 (+0.25)

Is Abaxis (ABAX) Worth Adding to Your Investment Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 1:35PM CST
On Nov 20, Zacks Investment Research upgraded home health and hospice care provider Abaxis Inc. (ABAX) to a Zacks Rank #2 (Buy).
ICUI: 83.38 (+1.63), ABAX: 58.48 (+0.22), PDCO: 48.79 (-0.02), OSUR: 10.26 (+0.25)

Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 7:00AM CST
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, announced today that Clint Severson, Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 10:30 a.m. ET. The conference will be held at The New York Palace Hotel in New York City.
ABAX: 58.48 (+0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Portillo's Faces Class Action: Investor Losses at Stake

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Investors Gear Up for Lennar Class Action Lawsuit

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...